Home > A. Molecular pathology > Targeted therapy > Therapeutical antibodies > ustekinumab
ustekinumab
Tuesday 10 May 2016
| WP |
Ustekinumab is directed against interleukin 12 (IL-12) and interleukin 23 (IL-23), naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders.
Ustekinumab (INN, experimental name CNTO 1275, proprietary commercial name Stelara, Centocor) is a human monoclonal antibody.
It is manufactured in the Netherlands.
It is directed against interleukin 12 and interleukin 23, naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders.
